SCHEMBL21449907

SCHEMBL21449907

COc1ccc(-n2cnc3ccc(-c4ccc(C(C)=O)cc4)cc32)cc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATM Q13315 4/20 0.59
KDR P35968 1/20 0.56
GSK3B P49841 2/20 0.56
ALDH1A1 P00352 5/20 0.54
HPGD P15428 3/20 0.54
HTT P42858 2/20 0.54
MAPK1 P28482 1/20 0.54
MAPK10 P53779 1/20 0.54
NCOA1 Q15788 1/20 0.54
NCOA3 Q9Y6Q9 1/20 0.54
RAB9A P51151 1/20 0.51
MAPT P10636 2/20 0.50
NPC1 O15118 1/20 0.49
TP53 P04637 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
FGFR1 P11362 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781279 0.89 KDR (0.68) ATMKDRGSK3BALDH1A1HPGD
SCHEMBL19781512 0.87 FGFR1 (0.52) ATMKDRGSK3BALDH1A1HPGD
SCHEMBL19781516 0.85 GSK3B (0.61) ATMKDRGSK3BALDH1A1HPGD
SCHEMBL18609552 0.84 KDR (0.74) ATMKDRGSK3BALDH1A1HPGD
SCHEMBL18584365 0.83 KDR (0.61) ATMKDRGSK3BALDH1A1HPGD
SCHEMBL21449915 0.82 ATM (0.57) ATMKDRGSK3BALDH1A1HPGD
SCHEMBL18609689 0.82 KDR (0.57) ATMKDRGSK3BALDH1A1HPGD
SCHEMBL3493713 0.81 FGFR1 (0.64) ATMGSK3BALDH1A1HPGDHTT
SCHEMBL21449910 0.81 KDR (0.56) ATMKDRGSK3BALDH1A1HPGD
SCHEMBL21449916 0.81 PTGS2 (0.61) ATMKDRGSK3BALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S ATM 4747/4885KDR 3283/4885GSK3B 4217/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S ATM 4747/4885KDR 3283/4885GSK3B 4217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.